Skip to main content

Table 1 Baseline demographics and clinical characteristics (n = 510)

From: Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

  Value, n (%)
Gender
 Male 376 (73.7)
 Female 134 (26.3)
Age, years
 6 to 12 years 366 (71.8)
 13 to 17 years 144 (28.2)
Mean ± SD 10.4 ± 3.1
Median (min to max) 10.0 (6 to 17)
Treatment Category
 Hospitalization 22 (4.3)
 Outpatient 488 (95.7)
Duration of ASD, years
  < 1 year 216 (42.4)
  ≥ 1 to < 2 years 46 (9.0)
  ≥ 2 to < 3 years 25 (4.9)
  ≥ 3 years 86 (16.9)
 Unknown 137 (26.9)
 Mean ± SD (n = 373) 1.70 ± 2.51
 Median (min to max) 0.50 (0 to 15.3)
Intellectual disability
 None 387 (75.9)
 Total 123 (24.1)
  Mild 68 (13.3)
  Moderate 30 (5.9)
  Severe 19 (3.7)
  Most severe 6 (1.2)
Comorbidities
 None 144 (28.2)
 Total 366 (71.8)
  ADHDa 271 (53.1)
  LDa 57 (11.2)
  Tic disordersa 35 (6.9)
  Sleep disordersa 90 (17.6)
Concomitants for ASD
 None 461 (90.4)
 Total 49 (9.6)
  Risperidonea 26 (5.1)
  Antidepressantsa 36 (7.1)
  ADHD drugsa 6 (1.2)
Concomitants for other condition
 None 257 (50.4)
 Total 253 (49.6)
  Methylphenidate hydrochlorideab 86 (16.9)
  Guanfacine hydrochlorideab 43 (8.4)
  Atomoxetine hydrochlorideab 42 (8.2)
  Risperidoneab 30 (5.9)
  Ramelteonab 17 (3.3)
  Sodium valproateab 12 (2.4)
  Yokukansanab 12 (2.4)
CGI-S
 1: Normal 1 (0.2)
 2: Minimally ill 1 (0.2)
 3: Mildly ill 42 (8.2)
 4: Moderately ill 282 (55.3)
 5: Makedly ill 150 (29.4)
 6: Severely ill 30 (5.9)
 7: Very severely ill 4 (0.8)
 Mean ± SD 4.3 ± 0.8
 Median (min to max) 4.0 (1 to 7)
  1. a: Multiple responses were allowed in a patient
  2. b: Drugs using in ≥2% of Patiants